Startseite Crystal structure of ethyl (E)-3-(cyclopropylamino)-2-(2,4-dichloro-5-fluorobenzoyl) acrylate, C15H14Cl2FNO3
Artikel Open Access

Crystal structure of ethyl (E)-3-(cyclopropylamino)-2-(2,4-dichloro-5-fluorobenzoyl) acrylate, C15H14Cl2FNO3

  • Han-Xiao Liao , Bei-Bei Ying , Chao Shen und Peng-Fei Zhang EMAIL logo
Veröffentlicht/Copyright: 10. Mai 2017

Abstract

C15H14Cl2FNO3, triclinic, P1̅ (no. 2), a = 8.5995(8) Å, b = 9.9579(9) Å, c = 10.1418(10) Å, α = 113.4900(10)°, β = 95.8730(10)°, γ = 96.1610(10)°, V = 781.81(13) Å3, Z = 2, Rgt(F) = 0.0282, wRref(F2) = 0.0788, T = 100(2)K.

CCDC no.:: 1495722

The crystal structure is shown in the figure. Tables 1 and 2 contain details on crystal structure and measurement conditions and a list of the atoms including atomic coordinates and displacement parameters.

Table 1

Data collection and handling.

Crystal:Colourless block
Size:0.20 × 0.20 × 0.20 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:4.4 cm−1
Diffractometer, scan mode:Bruker SMART, φ and ω
2θmax, completeness:50°, >99%
N(hkl)measured, N(hkl)unique, Rint:5448, 2737, 0.016
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 2379
N(param)refined:200
Programs:Bruker [1], SHELX [2], WinGX/ORTEP [3], OLEX2 [4]
Table 2

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
C10.2093(2)0.60661(19)0.13129(18)0.0180(4)
C20.1788(2)0.45305(19)0.06736(18)0.0209(4)
H20.20030.3996−0.02820.025*
C30.1167(2)0.37837(19)0.14470(19)0.0189(4)
C40.0846(2)0.45945(19)0.28283(18)0.0167(4)
C50.11564(19)0.61196(19)0.34668(18)0.0167(4)
H50.09430.66490.44240.020*
C60.17852(19)0.68844(18)0.27023(18)0.0152(4)
C70.2307(2)0.85472(19)0.34519(18)0.0163(4)
C80.12550(19)0.95872(18)0.35028(17)0.0145(3)
C9−0.04483(19)0.90967(18)0.29682(17)0.0146(4)
C10−0.2913(2)0.9771(2)0.2391(2)0.0209(4)
H10A−0.34520.94420.30530.025*
H10B−0.31170.89470.14070.025*
C11−0.3511(2)1.1115(2)0.2343(3)0.0382(5)
H11A−0.29561.14390.16970.057*
H11B−0.33171.19160.33260.057*
H11C−0.46511.08690.19760.057*
C120.1859(2)1.11044(18)0.40642(17)0.0155(4)
H120.11341.17440.40120.019*
C130.3889(2)1.32970(19)0.5171(2)0.0213(4)
H130.44291.36050.44850.026*
C140.4532(2)1.4164(2)0.6748(2)0.0285(5)
H14A0.54551.49580.70120.034*
H14B0.45111.36330.73910.034*
C150.2981(2)1.43934(19)0.6123(2)0.0241(4)
H15A0.20041.40040.63800.029*
H15B0.29481.53290.60010.029*
Cl10.08210(6)0.18670(5)0.07389(5)0.03043(15)
Cl20.29229(6)0.69761(5)0.03361(5)0.02949(14)
F10.02051(12)0.38588(11)0.35657(11)0.0240(2)
N10.33303(17)1.17296(15)0.46554(15)0.0172(3)
H10.40131.11600.47410.021*
O2−0.11463(13)0.78444(13)0.26150(13)0.0190(3)
O3−0.12146(13)1.01987(13)0.29207(13)0.0189(3)
O10.37304(14)0.89535(13)0.39948(14)0.0248(3)

Source of material

A mixture of 60 mL 1,2-dichlorobenzene and cyclopropylamine hydrochloride (5.61 g, 0.06 mol) was stirred at 180 °C. Formoxyl ethyl acetate sodium salt (8.28 g, 0.06 mol) was added in batches. The reaction was completely finished by circumfluence to repel water for 3 h. After cooling to room temperature, the reaction mixture was slowly added to a mixture of 2,4-dichloro-5-fluorobenzoyl chloride (13.65 g, 0.06 mol), trimethylamine (6.06, 0.06 mol) and 40 mL 1,2-dichlorobenzene at 25–35 °C. The temperature was at 50°C kept for three hours. When the reaction was complete, the mixture was filtered, and solid impurity was removed. The organic layer was washed with water (50 mL) and dried with MgSO4. The title compound was obtained after the solvent was removed under reduced pressure.

Experimental details

All H atoms were included in calculated positions and refined as riding atoms, with C—H in the 0.95–1.00 Å range and with Uiso(H) = 1.2Ueq(C, N) and 1.5Ueq(Cmethyl).

Discussion

Quinolones are one of the most widespread types of antibacterials in human daily lives [5]. Since the introduction of the first quinolone as a therapeutic agent of urinary tract infections [6], quinolones have become one of the main drugs to treat bacterial infections, widely used in the treatment of diseases including sexually transmitted diseases, urinary tract infections, chronic bronchitis, community acquired pneumonia, respiratory infections and so on [7]. Among these, the most notable ones are 4-quinolones [8], [9], [10], [11], [12], which form the core backbone of several quinolone-based and commercially-available antibiotics. For these reasons, it is necessary to develop simple and efficient approaches for the synthesis of 4-quinolones. So quinolone intermediates are a kind of important organic intermediate and play a vital role in the synthesis of quinolone main ring. In continuation of our previous work on the total synthesis of 4-quinolones, the structure of title compound was determined.

The compound crystallizes in the centrosymmetric triclinic space group with one molecule in the asymmetric unit. The amino group is involved in the donation of an intramolecular hydrogen bond to the benzoyl oxygen atom [D⋯A 2.643(2) Å and D–H⋯A 129°]. Bond lengths and angles are in the expected ranges.

Acknowledgement

The authors gratefully acknowledge the support from Zhejiang Provincial Natural Science Foundation of China (No. LZ13B020001), the National Natural Science Foundation of China (No. 21376058). The authors thank the responsible editor for providing the figure.

References

1 Bruker. SADABS, SMART and SAINT, Bruker AXS Inc., Madison, WI, USA, 2002.Suche in Google Scholar

2 Sheldrick, G. M.: A short history of SHELX. Acta Crystallogr. A64 (2008) 112–122.10.1107/S0108767307043930Suche in Google Scholar

3 Farrugia, L. J.: WinGX and ORTEP for Windows: an update. J. Appl. Crystallogr. 45 (2012) 849–854.10.1107/S0021889812029111Suche in Google Scholar

4 Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K.; Puschmann, H.: OLEX2: a complete structure solution, refinement and analysis program. J. Appl. Cryst. 42 (2009) 339–341.10.1107/S0021889808042726Suche in Google Scholar

5 Velema, W. A.; Berg, J. P.; van, d.; Hansen, M. J.; Szymanski, W.; Driessen, A. J. M.; Feringa, B. L.: Optical control of antibacterial activity. Nat. Chem. 5 (2013) 924–928.10.1038/nchem.1750Suche in Google Scholar

6 Lsher, G. Y.; Froelich, E. J.; Gruett, M. D.;Bailey, J. H.; Brundage, R. P.: 1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents. J. Med. Chem. 5 (1962) 1063–1065.10.1021/jm01240a021Suche in Google Scholar

7 Aldred, K. J.; Kerns, R. J.; Osheroff, N.: Mechanism of quinolone action and resistance. Biochemistry 53 (2014) 1565–1574.10.1021/bi5000564Suche in Google Scholar

8 Pescatori, L.; Metifiot, M.; Chung, S.; Masoaka, T.; Crucitti, G. C.; Messore, A.; Pupo, G.; Madia, V. N.; Saccoliti, F.; Scipione, L.; Tortorella, S.; Leva, F. S. D.; Cosconati, S.; Marinelli, L.; Novellino, E.; Le Grice, S. F.; Pommier, Y.; Marchand, C.; Costi, R.; Di Santo, R.: N-Substituted quinolinonyl diketo acid derivatives as HIV integrase strand transfer inhibitors and their activity against RNase H function of reverse transcriptase. J. Med. Chem. 58 (2015) 4610–4623.10.1021/acs.jmedchem.5b00159Suche in Google Scholar

9 Hays, E. E.; Wells, I. C.; Katzman, P. A.; Cain, C.; Jacobs, F. A.; Thayer, S. A.; Doisy, E. A.; Gaby, W.; Roberts, E.; Muir,R.: Antibiotic substances produced by Pseu-domonas aeruginosa. J. Biol. Chem. 159 (1945) 725–750.10.1016/S0021-9258(17)41580-8Suche in Google Scholar

10 Torii, S.; Okumoto, H.; Xu, L. H.: Palladium-catalyzed carbonylation to form 2-substituted 1,4-dihydro-4-oxo-quinoline. Tetrahedron Lett. 32 (1991) 237–240.10.1016/0040-4039(91)80864-3Suche in Google Scholar

11 Sánchez-Roselló, M.; Aceña, J. L.; Simón-Fuentes, A.; del Pozo, C.: A general overview of the organocatalytic intramolecular aza-Michael reaction. Chem. Soc. Rev. 43 (2014) 7430–7453.10.1039/C4CS00156GSuche in Google Scholar

12 Mondal, B.; Pan, S. C.: Primary amino acid catalyzed asymmetric intramolecular Mannich reaction for the synthesis of 2-aryl-2,3-dihydro-4-quinolones. Org. Biomol. Chem. 12 (2014) 9789–9792.10.1039/C4OB02146KSuche in Google Scholar

Received: 2016-12-16
Accepted: 2017-4-13
Published Online: 2017-5-10
Published in Print: 2017-7-26

©2017 Han-Xiao Liao et al., published by De Gruyter.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Artikel in diesem Heft

  1. Cover and Frontmatter
  2. Crystal structure of poly[diaqua-(μ2-4,4′-bipyridine-κ2N:N′)manganese(II)] bis(4-chlorobenzenesulfonate) – 4,4′-bipyridine – water (1/1/2) C42H40Cl2MnN6O10S2
  3. The crystal structure of 1,2-bis[2-methyl-5-(3-cyanophenyl)-3-thienyl]-3,3,4,4,5,5-hexafluoro-cyclopent-1-ene, C29H16F6N2S2
  4. Crystal structure of the first characterized polymeric copper and sodium complex diaqua-(tris-acetato-κO,O′)(μ2-acetato-κO′′)dinatrium copper(II) monohydrate, C8H18CuNa2O11
  5. The crystal structure of the Schiff base (E)-2,6-diisopropyl-N-(pyridin-3-yl-methylene)aniline, C18H22N2
  6. Crystal structure of methyl 2,7,7-trimethyl-4-(4-nitrophenyl)-5-oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylate, C20H22N2O5
  7. Crystal structure of bis(1,3-bis(diphenylphosphino)propane-κ2P,P′)silver(I) trifluorosulfonate–methanol (1:0.5), [Ag(C27H26P2)]SO3CF3⋅0.5CH3OH
  8. Crystal structure of μ-1,4-bis(diphenylphosphine)butane-2,9-dimethyl-1,10-phenanthroline-κ2N:N′-bis(cyano-κC)dicopper(I)]-water, C58H56Cu2N6O2P2
  9. Crystal structure of N2,N6-bis(1-hydrazinyl-2-methyl-1-oxopropan-2-yl) pyridine-2,6-dicarboxamide, C15H23N7O4
  10. Crystal structure of 1,3-dimethyl-2-phenyl-1H-perimidin-3-ium iodide, C19H17IN2
  11. Crystal structure of diaqua-(2,2′-(butane-1,4-diyl)-bis(5-carboxy-1H-imidazole-4-carboxylato)-κ4O,O′,N,N′)cadmium(II) monohydrate, C14H18O11N4Cd
  12. Crystal structure of ethyl (E)-3-(cyclopropylamino)-2-(2,4-dichloro-5-fluorobenzoyl) acrylate, C15H14Cl2FNO3
  13. Crystal structure of bis-(1-(4-chlorophenyl)-3-phenyl-4-thenoyl-1H-pyrazol-5-ol-κ2O,O′)-(N,N-dimethylformamide)zinc(II), C43H31Cl2N5O5S2Zn
  14. Crystal structure of tetrakis(μ3-2-(N-(2-hydroxyethyl)amino)ethoxo)-tetrachloro-tetra-cobalt(II) methanol solvate, C17H44Cl4Co4N4O9
  15. Crystal structure of 3-amino-1-(4-bromophenyl)-9-methoxy-1H-benzo[f]chromene-2-carbonitrile, C21H15BrN2O2
  16. Crystal structure of 2-amino-4-(4-isopropyl-phenyl)-3-cyano-5-oxo-4H,5H-pyrano[3,2-c]chromene, C22H18N2O3
  17. Crystal structure of 3-amino-8-methoxy-1-(4-methoxy phenyl)-1H-benzo[f]chromene-2-carbonitrile, C22H18N2O3
  18. Crystal structure of monoaqua-[6,6′-((1E,1′E)-(1,2-phenylene bis(azanylylidene))bis(methanylylidene))bis(4-bromo-2-nitrophenolato-κ4N,N′,O,O′)]zinc(II), C20H12Br2N4O7Zn
  19. Crystal structure of 11-(4-(dimethylamino)phenyl)-17-hydroxy-13-methyl-17-(prop-1-yn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one – acetonitril (1/2), C33H41N3O2
  20. Crystal structure of tert-butyl (phenylsulfinyl)carbamate, C11H15NO3S
  21. Crystal structure of catena-poly{diaqua-bis(3-(1H-1,2,4-triazol-1-yl)benzoato-κ2O:N)copper(II)} monohydrate, C18H18CuN6O7
  22. Crystal structure of tetraaqua-bis(3-(4H-1,2,4-triazol-4-yl)benzoato-κN)cobalt(II), C18H20CoN6O8
  23. The crystal structure of 4-bromo-N-cyclopropyl-2,5-difluorobenzenesulfonamide, C9H8BrF2NO2S
  24. Crystal structure of ([3,3′-bipyridine]-6,6′-dicarboxylato-κ2O:O′)-bis(1,2-bis(4-pyridyl)ethane-κ2N:N′)disilver(I) dihydrate, C37H35Ag2N5O6
  25. The crystal structure of (4-(1H-1,2,4-triazol-1-yl)benzoato-κN)-[4-(1H-1,2,4-triazol-1-yl)benzoic acid-κN]silver(I), C18H13AgN6O4
  26. Crystal structure of 3-(4-methoxyphenyl)-1-(4-methylphenyl)prop-2-en-1-one, C17H16O2
  27. Crystal structure of bis(2-((E)-((4-((E)-1-(ethoxyimino)ethyl)phenyl)imino)methyl)-5-methoxyphenolato-κ2O,N)copper(II), C36H38CuN4O6
  28. Crystal structure of poly[1,2-bis(1,2,4-triazol-4-yl)ethane-κ2N:N′]silver(I) bromate monohydrate]silver(I), C6H10AgBrN6O4
  29. The crystal structure of 2,3,5-triphenyl-2,3-dihydro-1H-tetrazol-1-ium 2,3-dioxoindoline-5-sulfonate, C27H19N5O5S
  30. Crystal structure of 3-(2-amino-1,3-selenazol-4-yl)-2H-chromen-2-one – dimethylformamide (1/1), C15H15N3O3Se
  31. Crystal structure of diethyl 3,3′-(diazene-1,2-diyl)(E)-dibenzoate, C18H18N2O4
  32. Crystal structure of cis-bis((1H-benzimidazol-2-yl)methanol-κN,O)-bis(isothiocyanato-κN)nickel(II), C18H16N6NiO2S2
  33. Crystal structure of bis(2-(2′-hydroxy-5′-methoxyphenyl)-1H-benzimidazole)boron – tetrahydrofuran (1/1), C36H37N4O6B
  34. Crystal structure of poly[aqua-bis(nitrato-κ2O,O′)-(μ3-1,3-benzimidazol-3-ium-1,3-diacetato-κ4O,O′:O′′:O′′′)dysprosium(III)], C11H11DyN4O11
  35. Crystal structure of n-butyl-tris(dicyclo-hexylamido)hafnium(IV), C40H75HfN3
  36. Crystal structure of (E)-1-[1-(3-chloro-4-fluoro-phenyl)ethylidene]-2-(2,4-dinitrophenyl)hydrazine, C28H20Cl2F2N8O8
  37. The crystal structure of ethyl 4-((2-hydroxybenzyl)amino)benzoate, a Schiff base, C16H17NO3
  38. Crystal structure of 3-(2-(4-isobutylphenyl)propanoyl)-1-methylimidazolidine-2,4-dione, C17H22N2O3
  39. Crystal structure of poly[(μ3-2-(pyrazin-2-ylthio)acetato-κ3N:O:S)silver(I)], C6H5AgN2O2S
  40. Crystal structure of (E)-1-(3-((E)-((2-hydroxynaphthalen-1-yl)methylene)amino)phenyl)ethanone O-benzyl oxime, C26H22N2O2
  41. Crystal structure of (E)-2,3-dihydroxybenzaldehyde O-(2-((((E)-1-(2,5-dihydroxyphenyl)ethylidene)amino)oxy)ethyl) oxime monohydrate, C17H20N2O7
  42. Crystal structure of 4-(chloromethyl)-3-nitrobenzoic acid, C8H6ClNO4
  43. Crystal stucture of 4-((10H-phenothiazin-10-yl)methyl)-2,6-di-tert-butylphenol, C27H31NOS
  44. The crystal structure of ethyl 1-(4-nitrophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate, C13H10F3N3O4
  45. Crystal structure of catena-poly[di-(μ3-oxido-κ3O:O:O)-tetraoxido-(μ2-5′-(pyrazin-2-yl)-1H,2′H-3,3′-bi(1,2,4-triazole)-κ2N:N′)dimolybdenum(VI)], C8H6Mo2N8O6
  46. Crystal structure of (3,6-dioxocyclohexa-1,4-diene-1,4-bis(olato)-κ4O,O′:O′′,O′′′)-bis(tris(2-pyridylmethyl)amine-κ4N,N′,N′′,N′′′))-dizinc(II) bis(hexafluorophosphate(V)), C42H38F12N8O4P2Zn2
  47. Crystal structure of catena-poly[hexakis(μ2-2-acetylphenolato-κ3O:O,O′)trimanganese(II)], C48H42Mn3O12
  48. The crystal structure of 2,2-difluoro-4-(trifluoromethyl)-2,5-dihydro-[1,3,2]dioxaborinino[5,4-c]chromen-3-ium-2-uide, C11H6BF5O3
  49. Crystal structure of methyl (E)-2-(4-(diethylamino)-2-hydroxybenzylidene)hydrazine-1-carboxylate, C13H19N3O3
  50. The crystal structure of tert-butyl 2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate, C10H15N3O2
  51. Crystal structure of 1,1-bis(η5-adamantylcyclopentadienyl)-3-phenyl-2-trimethylsilyl-2,3-dihydroisotitanazole, C42H55NSiTi
  52. Crystal structure of 2-(4-(2-(4-benzylpiperazin-1-yl)ethyl)benzyl)isoindoline-1,3-dione, C28H29N3O2
  53. Important impurity of Flupirtine – a single crystal study on ethyl (6-amino-5-((ethoxycarbonyl)amino)pyridin-2-yl)(4-fluorobenzyl)carbamate, C18H21FN4O4
  54. Crystal structure of ethyl 3-(4-methoxyphenyl)-1-(2-(4-methoxyphenyl)-2-oxoethyl)-1H-pyrazole-5-carboxylate, C22H22N2O5
  55. Crystal structure of 2,3,9,10-tetramethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium 5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-olate methanol solvate, C37H35N1O10
  56. The crystal structure of the inner salt of 2-[(aminoiminomethyl)amino]ethylcarbamic acid [systematic name: (2-((diaminomethylene)ammonio)ethyl)carbamate], C4H10N4O2
  57. Crystal structure of (8-hydroxy-5-nitroquinolinium) perchlorate – 8-hydroxy-5-nitroquinoline (1/1), C18H13ClN4O10
  58. The crystal structure of (5-methyl-1,2,4-oxadiazol-3-yl)ferrocene, C13H12FeN2O
  59. Crystal structure of methyl 1-(2-(fluorosulfonyl)ethyl)-2-oxocyclopentanecarboxylate, C9H13FO5S
  60. Crystal structure of the triclinic modification of 1-methyl-4-nitroimidzole, C4H5N3O2
  61. Corrigendum
  62. Crystal structure of 4-bromo-2-(1H-pyrazol-3-yl)phenol, C9H7BrN2O
Heruntergeladen am 30.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2016-0320/html
Button zum nach oben scrollen